Research monograph / class comparison
Sermorelin vs Ipamorelin: How the Two Secretagogue Classes Differ in the Research
Same axis, different doors. A GHRH-receptor analog set beside a ghrelin-receptor releasing peptide — the mechanism contrast, read from the literature.
In plain English
Sermorelin vs ipamorelin is a comparison of two ways to make the body release its own growth hormone (GH). Sermorelin copies GHRH — the brain's natural "make GH" signal — and works through the GHRH receptor. Ipamorelin is a different kind of molecule (a growth-hormone-releasing peptide, or GHRP) that works through the ghrelin receptor — a separate switch for the same gland. Think of them as two different keys that open two different locks on the same door. Both raise GH; neither is the other; and because they hit different receptors, researchers sometimes study them together.
Sermorelin vs ipamorelin: GHRH receptor vs ghrelin receptor
The core distinction is the receptor. Sermorelin is a GHRH analog — the native GHRH(1-29) fragment — acting on the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on pituitary somatotrophs, signaling through cAMP and PKA to release GH [13]. Ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin/GHS receptor — a different receptor, a different signaling entry point, within the same somatotropic axis [14].
That is why the two are sometimes studied or discussed together: they stimulate GH through complementary mechanisms, so combining them probes whether two doors open wider than one. But they are not interchangeable. Sermorelin amplifies the body's own GHRH signal; a GHRP mimics ghrelin's separate signal. The choice between them is a choice between mechanisms, not a choice between stronger and weaker versions of the same thing. This site documents the sermorelin side of that comparison in detail; the ghrelin-receptor pharmacology of ipamorelin is its own literature.
Why the feedback architecture differs
Because sermorelin works upstream through the native GHRH pathway, the body's feedback brakes — somatostatin and IGF-1 — continue to regulate the GH it elicits, preserving a pulsatile, self-limiting pattern [4]. An editorial framed this physiologic, feedback-preserving quality as a potential advantage of GHRH-secretagogue stimulation over directly supplying recombinant GH [4]. GHRPs engage the ghrelin receptor and a partly different regulatory context. The practical consequence the literature emphasizes for sermorelin is that GH stays within the body's own feedback envelope rather than being driven to flat, supraphysiologic levels [2][4].
Sermorelin vs tesamorelin: native fragment vs stabilized GHRH analog
A more direct comparison than ipamorelin is sermorelin vs tesamorelin, because both act on the GHRH receptor — they are the same class. The difference is stabilization. Sermorelin is the native GHRH(1-29) fragment with a short (~10-12 minute) plasma half-life [3]. Tesamorelin is a stabilized synthetic GHRH analog engineered for a longer, more sustained action, and it is the analog that carries most of the controlled adult outcome data in this family: it significantly reduced visceral fat in HIV-associated fat accumulation, and in a 20-week trial it improved cognition, raised IGF-1 by 117%, and cut percent body fat by 7.4% in older adults [6][11].
This is the honest reason the sermorelin adult-outcome literature looks thinner than its marketing: many of the strongest GHRH-analog results were generated with tesamorelin, not with native sermorelin. When a summary attributes "GHRH analog" benefits to sermorelin, check whether the underlying trial used the stabilized analog instead [6].
What the comparison does not settle
No study in this record pits native sermorelin head-to-head against ipamorelin on a clinical outcome, so the comparison is mechanistic rather than a measured winner. What can be said with confidence is the architecture: sermorelin = GHRH receptor, native fragment, short half-life, feedback-preserved pulsatile GH [3][4]; ipamorelin = ghrelin/GHS receptor, a separate GHRP mechanism [14]; tesamorelin = same receptor as sermorelin but stabilized and longer-acting, and the source of most controlled adult data [6]. Anyone weighing the three should weigh mechanisms and the strength of each compound's own evidence, not a head-to-head trial that does not exist.